Adverse events304

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 304

Type	Event	Organ system	Group	Affected	At risk
other	Aspartate aminotransferase increased	Investigations	Block 1	15	35
other	Aspartate aminotransferase increased	Investigations	Block 2a - Dose Level 1: Cytarabine 3000mg/m^2/Dose Every 12 Hours	0	7
other	Aspartate aminotransferase increased	Investigations	Block 2b - Dose Level 1: Venetoclax 240mg/m^2 for 21 Doses	0	16
other	Aspartate aminotransferase increased	Investigations	Post Therapy Follow-up		33
other	Alanine aminotransferase increased	Investigations	Block 1	11	35
other	Alanine aminotransferase increased	Investigations	Block 2a - Dose Level 1: Cytarabine 3000mg/m^2/Dose Every 12 Hours	1	7
other	Alanine aminotransferase increased	Investigations	Block 2b - Dose Level 1: Venetoclax 240mg/m^2 for 21 Doses	1	16
other	Alanine aminotransferase increased	Investigations	Post Therapy Follow-up		33
other	Hypocalcemia	Metabolism and nutrition disorders	Block 1	10	35
other	Hypocalcemia	Metabolism and nutrition disorders	Block 2a - Dose Level 1: Cytarabine 3000mg/m^2/Dose Every 12 Hours	0	7
other	Hypocalcemia	Metabolism and nutrition disorders	Block 2b - Dose Level 1: Venetoclax 240mg/m^2 for 21 Doses	0	16
other	Hypocalcemia	Metabolism and nutrition disorders	Post Therapy Follow-up		33
other	Hypokalemia	Metabolism and nutrition disorders	Block 1	11	35
other	Hypokalemia	Metabolism and nutrition disorders	Block 2a - Dose Level 1: Cytarabine 3000mg/m^2/Dose Every 12 Hours	0	7
other	Hypokalemia	Metabolism and nutrition disorders	Block 2b - Dose Level 1: Venetoclax 240mg/m^2 for 21 Doses	0	16
other	Hypokalemia	Metabolism and nutrition disorders	Post Therapy Follow-up		33
other	Hypoalbuminemia	Metabolism and nutrition disorders	Block 1	6	35
other	Hypoalbuminemia	Metabolism and nutrition disorders	Block 2a - Dose Level 1: Cytarabine 3000mg/m^2/Dose Every 12 Hours	0	7
other	Hypoalbuminemia	Metabolism and nutrition disorders	Block 2b - Dose Level 1: Venetoclax 240mg/m^2 for 21 Doses	0	16
other	Hypoalbuminemia	Metabolism and nutrition disorders	Post Therapy Follow-up		33

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05192889/events

API reference For AI assistants

Adverse events304

Sources 3

Read this list from software.